HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: The number of clinical trials are investigating the combined treatment of HDAC inhibitors with rituximab in B-cell lymphoma, with lenalidomide in MM, and with brentuximab vedotin in CTCL patients.